As a trusted leader in the immunotherapy field, the Society for Immunotherapy of Cancer (SITC) collaborates with other groups to contribute toward high-quality educational programming on tumor immunology and cancer immunotherapy.
Through these educational partnerships, SITC is able to bring high quality, timely cancer immunotherapy information to learners around the world from a variety of backgrounds including scientists, academicians, researchers, clinicians, government representatives and industry leaders.
SITC offers various levels of support for the programs below, such as sharing information about unique programs, providing expert speakers to enhance programming and organizing immunotherapy sessions at relevant association meetings.
If you'd like to get in touch with the society to discuss Collaborative Education Programs, please email the SITC Live Education Department at Education@sitcancer.org.
Hello SITC community! I will appreciate any insights going forward for AML patients who have progressed after receiving allogeneic BMT and currently enrolled for treatment with Gilteritinib. Will such patients benefit from currently approved immunotherapies ...
This message was posted by a user wishing to remain anonymous Given that each cytokine degrades at different points in the media...while setting up a multiplex in vitro cytokine profiling assay, (with PBMCs post treatment) what is the best time point ...
Dear colleagues, Dear participants,
I would like to invite you to attend and participate actively in our
ISOBM (International Society of Oncology and BioMarkers) 2018 CONGRESS, to be held in Hamburg, Germany, on November 24 - 27, 2018. ...
Animal models have shown intestinal microbiota are crucial for therapeutic efficacy for CTLA4 blockade ( has decreased tumor size) and anti-PD1 psychotherapies.That the microbiome may be a target that can be modulated to enhance treatment responses. Theoretically, ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org